(Q38812608)

English

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder

scientific article published on 29 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

pharmacogenomics

1 reference

based on heuristic

inferred from title

6

object named as

Mark Helfand

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Kimberly Peterson

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Eric Dieperink

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Johanna Anderson

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Erin Boundy

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lauren Ferguson

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

publication date

29 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

234

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1649-1661

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Commercial pharmacogenetic-based decision-support tools in psychiatry

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Pharmacogenetic Tests in Psychiatry: From Fear to Failure to Hype

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Using a pharmacogenomic algorithm to guide the treatment of depression

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Chapter 11: challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Thresholds for the cost-effectiveness of interventions: alternative approaches

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Methods for the drug effectiveness review project

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Direct-to-consumer genome testing: opportunities for pharmacogenomics research?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Antidepressant pharmacogenetics

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Contribution of common genetic variants to antidepressant response

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

What is the price of life and why doesn't it increase at the rate of inflation?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-017-4622-9

21 January 2018

Pharmacogenetic testing in psychiatry: not (quite) ready for primetime

1 reference

https://pubmed.ncbi.nlm.nih.gov/28456840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).

1 reference

https://pubmed.ncbi.nlm.nih.gov/28456840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/28456840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/28456840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28456840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-017-4622-9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38812608&oldid=2202100232"